Hexavest buys $86,389,173 stake in Valeant Pharmaceuticals Intl Inc (VRX)

Valeant Pharmaceuticals Intl Inc (VRX) : Hexavest scooped up 1,973,087 additional shares in Valeant Pharmaceuticals Intl Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 3,765,875 shares of Valeant Pharmaceuticals Intl Inc which is valued at $86,389,173.Valeant Pharmaceuticals Intl Inc makes up approximately 1.57% of Hexavest’s portfolio.

Other Hedge Funds, Including , Creative Planning boosted its stake in VRX in the latest quarter, The investment management firm added 39,565 additional shares and now holds a total of 273,620 shares of Valeant Pharmaceuticals Intl Inc which is valued at $6,276,843. Valeant Pharmaceuticals Intl Inc makes up approx 0.04% of Creative Planning’s portfolio. Addison Capital Co added VRX to its portfolio by purchasing 9,142 company shares during the most recent quarter which is valued at $215,660. Valeant Pharmaceuticals Intl Inc makes up approx 0.19% of Addison Capital Co’s portfolio.Academy Capital Management Inctx boosted its stake in VRX in the latest quarter, The investment management firm added 76,638 additional shares and now holds a total of 649,959 shares of Valeant Pharmaceuticals Intl Inc which is valued at $15,053,050. Valeant Pharmaceuticals Intl Inc makes up approx 4.03% of Academy Capital Management Inctx’s portfolio.

Valeant Pharmaceuticals Intl Inc closed down -0.65 points or -2.76% at $22.94 with 1,06,50,739 shares getting traded on Tuesday. Post opening the session at $23.42, the shares hit an intraday low of $22.72 and an intraday high of $23.715 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Valeant Pharmaceuticals Intl Inc reported $1.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $1.48. The company had revenue of $2420.20 million for the quarter, compared to analysts expectations of $2451.77 million. The company’s revenue was down -11.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $2.14 EPS.

Many Wall Street Analysts have commented on Valeant Pharmaceuticals Intl Inc. Shares were Reiterated by RBC Capital Mkts on Oct 12, 2016 to “Sector Perform” and Lowered the Price Target to $ 35 from a previous price target of $36 .Deutsche Bank Resumed Valeant Pharmaceuticals Intl Inc on Sep 20, 2016 to “Hold”, Price Target of the shares are set at $30.Company shares were Upgraded by Morgan Stanley on Aug 17, 2016 to ” Overweight”, Firm has raised the Price Target to $ 42 from a previous price target of $33 .

Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.

Leave a Reply

Valeant Pharmaceuticals Intl Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Valeant Pharmaceuticals Intl Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.